Drug Profile
Tulobuterol transdermal - NAL Pharma
Alternative Names: NAL 6328Latest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antiasthmatics; Bronchodilators
- Mechanism of Action Beta 2 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Respiratory tract disorders
Most Recent Events
- 26 May 2022 Tulobuterol transdermal is still in clinical trials for Respiratory tract disorders (NAL Pharma pipeline, May 2022)
- 28 Dec 2019 No recent reports of development identified for clinical-Phase-Unknown development in Respiratory-tract-disorders in Unknown (Transdermal, Patch)
- 12 Dec 2016 Chemical structure information added